ProQR Therapeutics N.V.

NASDAQ:PRQR

Biotechnology

Healthcare
$1.10 +12.28%

+$0.21 today

Market cap
$155.23M
Beta
0.06
P/E (TTM)
-3.8
EPS (TTM)
-$0.43
52W Low $1.33High $3.10

Volume 0.88M

Average 0.62M

PRQR Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

ProQR Therapeutics N.V.NASDAQ: PRQR

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables outflow grows to €0

Q1 FY2026 accounts receivables was €0, compared with €0 a year earlier. Trailing-twelve-month accounts receivables was €0.

Context

  • Accounts receivables amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near €0 or moves back toward the trailing-twelve-month quarterly average of €0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
€0— QoQ
Last fiscal yearDec 2025
€0— YoY
LTMMar 2026
€0— YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

EUR · from the cash flow

Latest · FY2025
0 EUR
Year-over-year change
—

Accounts Receivables vs competitors

How PRQR compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Accounts receivables amounts to 0.0% of revenue for PRQR, versus a peer median of 25.6%.
PRQR Competitors
Accounts Receivables for PRQR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$13.31M USD+6.6%—29.4%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$12.33M USD+56.3%+89.9%5.7%
IMMPImmutep LimitedFY2025A$2.52M AUD-518.5%+3.8%49.9%
EDITEditas Medicine, Inc.LTM Mar 2026$2.08M USD+685.7%—5.4%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$1.26M USD-98.3%—21.9%
MREOMereo BioPharma Group plcLTM Mar 2026$345.69K USD+257.1%—69.1%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$59.83K USD-100.0%——
PRQRProQR Therapeutics N.V.LTM Mar 2026€0 EUR——0.0%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$0 USD———
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$0 USD———
ZURAZura Bio LimitedLTM Mar 2026$0 USD———
Peer median (excluding PRQR) —+6.6%+46.9%25.6%

Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(60.8M)(64.2M)(27.74M)(27.76M)(40.52M)
Depreciation & Amortization2.33M2.52M2.51M2.76M2.6M
Deferred Income Tax117K96K(78K)(197K)0
Stock-Based Compensation6.22M2.87M3.11M2.54M0
Change in Working Capital25.01M(4.99M)48.96M(13.26M)(16.73M)
Accounts Receivables00000
Inventory00000
Accounts Payables00000
Other Working Capital25.01M(4.99M)48.96M(13.26M)(16.73M)
Other Non-Cash Items1.11M(4.8M)(5.21M)(474K)3.94M
Operating Cash Flow(26.01M)(68.51M)21.55M(36.39M)(50.71M)
Capital Expenditures(484K)(708K)(1.37M)(1.42M)(979.75K)
Acquisitions (Net)00000
Purchases of Investments000(17M)0
Sales of Investments00017M0
Other Investing Activities59K6K5.65M(2.66M)0
Investing Cash Flow(425K)(702K)4.28M(4.07M)(979.74K)
Debt Repayment26.84M(45.05M)(2.63M)(1.58M)(1.91M)
Common Stock Issued108.48M14.12M071.64M66.28K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.52M34K354K223K75.19K
Financing Cash Flow136.83M(30.89M)(2.28M)70.28M(1.76M)
Effect of Forex Changes1.29M7.35M599K673K14.15M
Net Change in Cash111.69M(92.75M)24.15M30.48M(39.3M)
Free Cash Flow(26.5M)(69.22M)20.18M(37.81M)(51.69M)

ProQR Therapeutics N.V.

NASDAQ:PRQR

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.